Efficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN
Authors:
- Luca ScaralloLSLuca Scarallo
- Paolo LionettiPLPaolo Lionetti
- Lauren CollenLCLauren Collen
- Victoria RiedlVRVictoria Riedl
- Christian JakobsenCJChristian Jakobsen
- Gemma Pujol‐MuncunillGPGemma Pujol‐Muncunill
- Kaija‐Leena KolhoKKKaija‐Leena Kolho
- Marta Velasco Rodriguez‐BelvisMRMarta Velasco Rodriguez‐Belvis
- Katarina MitrovaKMKatarina Mitrova
- Benedicte PigneurBPBenedicte Pigneur
Open Access
- 5 November 2026
- journal article
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Abstract
Objective: We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods: A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results: Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age <2 years old. Thirty‐seven (38.5%) patients received ustekinumab, 67 (69.7%) vedolizumab, and 11 (11.5%) both drugs. Median (Q1–Q3) follow‐up time was 11 (6–26) and 14 (7–39) months for ustekinumab and vedolizumab, respectively. Eighty (84.2%) patients were previously treated with infliximab, 23 (24.2%) with adalimumab, and 20 (20.8%) with both. The median (Q1–Q3) time from diagnosis to vedolizumab and ustekinumab initiation was 15 (9–26) and 20 (11–36) months, respectively. Ustekinumab‐treated patients achieved clinical remission in 24.3%, 51.4%, and 40.5% at end of induction, week 26, and week 52, with steroid‐free remission in 18.9%, 45.9%, and 35.3%, respectively. Vedolizumab‐treated patients achieved clinical remission in 29%, 47.5%, and 40.3%, with steroid‐free clinical remission (SFCR) rates of 10.4%, 43.3%, and 37.3% at the same time points. Infectious adverse events were reported in 3 (8.3%) of ustekinumab‐treated and 5 (7.6%) vedolizumab‐treated patients, none severe. Conclusions: Ustekinumab and vedolizumab demonstrated high therapeutic durability in patients with VEO‐IBD; 1‐year rates of SFCR were modest.Keywords
This publication has 37 references indexed in Scilit:
- Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI studyJournal of Pediatric Gastroenterology and Nutrition, 2026
- Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort studyJournal of Gastroenterology, 2026
- Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paperJournal of Pediatric Gastroenterology and Nutrition, 2025
- Efficacy of vedolizumab and ustekinumab in pediatric‐onset inflammatory bowel disease: A real‐world multicenter studyJournal of Pediatric Gastroenterology and Nutrition, 2024
- Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension resultsJournal of Pediatric Gastroenterology and Nutrition, 2024
- Effectiveness and Safety of Ustekinumab in Pediatric Ulcerative Colitis: A Multi-center Retrospective Study from the Pediatric IBD Porto Group of ESPGHANPediatric Drugs, 2024
- STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHANEuropean Journal of Pediatrics, 2024
- Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitisJournal of Pediatric Gastroenterology and Nutrition, 2024
- Catalyzing change: Implementing standardised reporting in monogenic inflammatory bowel disease researchJournal of Pediatric Gastroenterology and Nutrition, 2024
- Mathematical weighting of the pediatric Crohnʼs disease activity index (PCDAI) and comparison with its other short versionsInflammatory Bowel Diseases, 2012